Nasdaq listed Cancer Genetics Inc, has announced today the appointment of Mandar Kulkarni as chief technology officer of Cancer Genetics, India, based in Hyderabad. In his role, Kulkarni will lead efforts to expand CG India's technology programmes and initiatives with a focus on accelerating development and innovation, the company said in a press release.
Prior to joining CG India, Kulkarni was head of molecular biology and genomics at Sandor Lifesciences, where his team designed and executed next-generation sequencing, bioinformatics, and microarray initiatives.
"Mandar's expertise in leading teams focused on next-generation sequencing and bioinformatics is completely aligned with CG India's vision," said Panna Sharma, President and CEO of Cancer Genetics.
CG Inc specialises in DNA-based cancer diagnostics. The company's tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients.